Haverford Trust Co Grows Stock Position in Bristol-Myers Squibb (NYSE:BMY)

Haverford Trust Co lifted its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 0.6% in the 3rd quarter, Holdings Channel.com reports. The firm owned 67,229 shares of the biopharmaceutical company’s stock after buying an additional 382 shares during the quarter. Haverford Trust Co’s holdings in Bristol-Myers Squibb were worth $3,478,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also modified their holdings of the company. Atomi Financial Group Inc. acquired a new stake in Bristol-Myers Squibb in the first quarter valued at $231,000. TD Asset Management Inc grew its holdings in Bristol-Myers Squibb by 2.7% in the first quarter. TD Asset Management Inc now owns 1,648,245 shares of the biopharmaceutical company’s stock valued at $89,384,000 after purchasing an additional 42,682 shares during the last quarter. HBK Sorce Advisory LLC grew its holdings in Bristol-Myers Squibb by 3.7% in the first quarter. HBK Sorce Advisory LLC now owns 32,578 shares of the biopharmaceutical company’s stock valued at $1,767,000 after purchasing an additional 1,159 shares during the last quarter. Wintrust Investments LLC grew its holdings in Bristol-Myers Squibb by 9.7% in the first quarter. Wintrust Investments LLC now owns 39,652 shares of the biopharmaceutical company’s stock valued at $2,150,000 after purchasing an additional 3,515 shares during the last quarter. Finally, TCTC Holdings LLC grew its holdings in Bristol-Myers Squibb by 0.9% in the first quarter. TCTC Holdings LLC now owns 443,544 shares of the biopharmaceutical company’s stock valued at $24,053,000 after purchasing an additional 3,909 shares during the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently commented on the company. Leerink Partnrs raised Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a research note on Tuesday. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $50.00 price objective on shares of Bristol-Myers Squibb in a research note on Friday, October 18th. Barclays increased their price objective on Bristol-Myers Squibb from $42.00 to $43.00 and gave the company an “underweight” rating in a research note on Monday, October 7th. BMO Capital Markets increased their price objective on Bristol-Myers Squibb from $57.00 to $61.00 and gave the company a “market perform” rating in a research note on Tuesday. Finally, Leerink Partners raised Bristol-Myers Squibb from a “market perform” rating to an “outperform” rating and raised their price target for the stock from $55.00 to $73.00 in a research note on Tuesday. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating, two have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $54.07.

Bristol-Myers Squibb Stock Performance

Bristol-Myers Squibb stock opened at $58.43 on Thursday. The stock’s 50-day moving average is $52.24 and its 200-day moving average is $46.99. The company has a market cap of $118.51 billion, a price-to-earnings ratio of -16.28, a price-to-earnings-growth ratio of 21.34 and a beta of 0.44. The company has a debt-to-equity ratio of 2.83, a current ratio of 1.24 and a quick ratio of 1.09. Bristol-Myers Squibb has a 12 month low of $39.35 and a 12 month high of $61.08.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.80 EPS for the quarter, beating the consensus estimate of $1.49 by $0.31. The business had revenue of $11.89 billion for the quarter, compared to the consensus estimate of $11.26 billion. Bristol-Myers Squibb had a positive return on equity of 11.94% and a negative net margin of 15.30%. The company’s revenue was up 8.4% on a year-over-year basis. During the same period last year, the business posted $2.00 EPS. Equities analysts anticipate that Bristol-Myers Squibb will post 0.92 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, November 1st. Investors of record on Friday, October 4th were issued a dividend of $0.60 per share. The ex-dividend date was Friday, October 4th. This represents a $2.40 annualized dividend and a dividend yield of 4.11%. Bristol-Myers Squibb’s payout ratio is currently -66.85%.

Insider Activity at Bristol-Myers Squibb

In related news, SVP Phil M. Holzer sold 700 shares of the firm’s stock in a transaction dated Monday, November 4th. The stock was sold at an average price of $55.62, for a total transaction of $38,934.00. Following the sale, the senior vice president now directly owns 11,760 shares in the company, valued at approximately $654,091.20. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other Bristol-Myers Squibb news, EVP Samit Hirawat acquired 1,830 shares of the company’s stock in a transaction on Friday, November 1st. The shares were bought at an average cost of $54.67 per share, for a total transaction of $100,046.10. Following the acquisition, the executive vice president now directly owns 62,109 shares of the company’s stock, valued at $3,395,499.03. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Phil M. Holzer sold 700 shares of Bristol-Myers Squibb stock in a transaction that occurred on Monday, November 4th. The stock was sold at an average price of $55.62, for a total value of $38,934.00. Following the sale, the senior vice president now owns 11,760 shares in the company, valued at $654,091.20. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.09% of the company’s stock.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.